Literature DB >> 16420083

Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses.

Jose de Leon1, Margaret T Susce, Francisco J Diaz, Diego M Rendon, Diana M Velásquez.   

Abstract

BACKGROUND: Co-occurrence of substance use disorders and severe mental illnesses (SMIs) is a major U.S. public health issue, although the role of tobacco is usually neglected. This study explored variables associated with alcohol, drug, and smoking cessation in a naturalistic setting.
METHOD: Logistic regression was used to study variables associated with cessation of alcohol and drug use disorder and daily smoking in 560 SMI inpatients and outpatients from central Kentucky facilities. Patients with a lifetime history of alcohol or drug use disorder were considered to be in cessation if they had not suffered from abuse or dependence during the last year. Alcohol and drug use disorder diagnoses were determined using the Clinician Rating of Alcohol and Drug Use Disorder. Patients were recruited from July 2000 to March 2003.
RESULTS: The cessation rates for alcohol and drug use disorders were, respectively, 44% (95% CI = 39% to 49%) and 46% (CI = 40% to 51%); these were higher than the daily cigarette smoking cessation rate of 10% (CI = 7% to 13%). Drug use disorders (p < or = .02), outpatient status (p < .001), and having a medical complication of obesity (diabetes mellitus, hypertension, or hyperlipidemia; p < .001) were significantly associated with alcohol cessation. Alcohol use disorder (p < .001), starting treatment with psychiatric medications after 33 years of age (p < .001), taking these medications for 14 years or more (p = .02), schizophrenia diagnosis (p < .001), outpatient status (p = .03), and obesity (p = .04) were significantly associated with drug cessation. Cessation of daily smoking was associated with hypertension (p = .02), late start of treatment with psychiatric medications (> 33 years old; p = .01), and lack of lifetime drug abuse (p < .001).
CONCLUSIONS: These results are limited by the cross-sectional and naturalistic design but suggest that public health experts, researchers, and clinicians need to mindfully address smoking cessation in patients with SMIs. Clinicians may want to consider that medical illnesses may motivate patients with SMIs to stop substance abuse and that patients with SMIs who abuse both alcohol and drugs rarely stop abusing just one of them.

Entities:  

Mesh:

Year:  2005        PMID: 16420083     DOI: 10.4088/jcp.v66n1112

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Smoking cessation in patients with psychiatric disorders.

Authors:  Alan J Gelenberg; Jose de Leon; A Eden Evins; Joseph J Parks; Nancy A Rigotti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

2.  Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia.

Authors:  Deanna L Kelly; Heather G Raley; Suzanne Lo; Katherine Wright; Fang Liu; Robert P McMahon; Eric T Moolchan; Stephanie Feldman; Charles M Richardson; Heidi J Wehring; Stephen J Heishman
Journal:  Schizophr Bull       Date:  2010-11-01       Impact factor: 9.306

Review 3.  Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings.

Authors:  Jose de Leon; Francisco J Diaz
Journal:  Hum Genet       Date:  2011-12-22       Impact factor: 4.132

4.  Tobacco use among those with serious psychological distress: results from the national survey of drug use and health, 2002.

Authors:  Brett T Hagman; Cristine D Delnevo; Mary Hrywna; Jill M Williams
Journal:  Addict Behav       Date:  2007-11-17       Impact factor: 3.913

5.  Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness.

Authors:  Risa B Gershon Grand; Sun Hwang; Juliette Han; Tony George; Arthur L Brody
Journal:  J Clin Psychiatry       Date:  2007-06       Impact factor: 4.384

6.  Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Elaine Weiner; Douglas L Boggs; Dwight Dickinson; Robert R Conley; Robert W Buchanan
Journal:  Schizophr Res       Date:  2008-06-11       Impact factor: 4.939

7.  Clinical characteristics of heavy and non-heavy smokers with schizophrenia.

Authors:  Heidi J Wehring; Fang Liu; Robert P McMahon; Kristen M Mackowick; Raymond C Love; Lisa Dixon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-10       Impact factor: 4.939

8.  Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder.

Authors:  Sung-Wan Kim; Seetal Dodd; Lesley Berk; Jayashri Kulkarni; Anthony de Castella; Paul B Fitzgerald; Jae-Min Kim; Jin-Sang Yoon; Michael Berk
Journal:  Psychiatry Investig       Date:  2015-07-06       Impact factor: 2.505

9.  ADGRL3 (LPHN3) variants predict substance use disorder.

Authors:  Mauricio Arcos-Burgos; Jorge I Vélez; Ariel F Martinez; Marta Ribasés; Josep A Ramos-Quiroga; Cristina Sánchez-Mora; Vanesa Richarte; Carlos Roncero; Bru Cormand; Noelia Fernández-Castillo; Miguel Casas; Francisco Lopera; David A Pineda; Juan D Palacio; Johan E Acosta-López; Martha L Cervantes-Henriquez; Manuel G Sánchez-Rojas; Pedro J Puentes-Rozo; Brooke S G Molina; Margaret T Boden; Deeann Wallis; Brett Lidbury; Saul Newman; Simon Easteal; James Swanson; Hardip Patel; Nora Volkow; Maria T Acosta; Francisco X Castellanos; Jose de Leon; Claudio A Mastronardi; Maximilian Muenke
Journal:  Transl Psychiatry       Date:  2019-01-29       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.